Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarucizumab reversal of dabigatran anticoagulation in emergency bleeding or urgent procedures
NL-OMON42113Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of idarucizumab in dabigatran-induced anticoagulation requiring urgent reversal, Not applicable and intracerebral hemorrhage (ICH) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Reversal of anticoagulant effect of dabigatran. Started Feb 2015; status: active, not recruiting.
02
Drugs
idarucizumab
03
Conditions
dabigatran-induced anticoagulation requiring urgent reversalNot applicableintracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NL-OMON42113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42113.